Colorado’s HB 26-1325 is the most significant expansion of the state’s natural medicine program since the Natural Medicine Health Act first became law. The bill establishes an ibogaine research pilot...

Dr. Bill Detmer, CEO of Unbound Medicine, hosts Dr. Paul Nestadt and Dr. Mary Elizabeth “Bit” Yaden from the Johns Hopkins School of Medicine for a discussion on the evolving field of psychedelic medicine. Their conversation will explore practical strategies for patient education and innovative approaches to expanding mental health care capacity. Attendees will gain actionable insights to navigate emerging treatments and support informed conversations with patients. A live Q&A will follow the discussion.

The popularity of breathwork as a therapeutic tool for psychological distress is rapidly expanding. Breathwork practices that increase ventilatory rate or depth, facilitated by music, can evoke subjec...

The Pentagon will begin testing service members for psilocin, the hallucinogenic compound produced when psilocybin mushrooms, also known as magic

The first-of-its-kind case is putting Utah’s new religious freedom law to the test

Arizona allocates funding for ibogaine research, Reason Foundation to testify at Mississippi informational hearing about ibogaine, and more.

Psilocybin therapy can help low-income people suffering from depression, according to a new study from Oregon researchers.

Psilocybin holds promise as a treatment for mental illnesses. One dose of psilocybin induces structural remodeling of dendritic spines in the medial frontal cortex in mice. The dendritic spines would ...

University of New Mexico researchers are joining a multi-site clinical trial of an experimental psychedelic drug intended to alleviate the mental suffering many patients experience when they receive a...

Nature Neuroscience - Aarrestad et al. show that, in contrast to psychedelics, the nonhallucinogenic psychoplastogen tabernanthalog promotes neuroplasticity through 5-HT2AR activation without...

Understanding exactly how psychedelics promote new connections in the brain is critical to developing targeted, non-hallucinogenic therapeutics that can treat neurodegenerative and neuropsychiatric di...

Alzheimer's disease (AD) is a major neurodegenerative disorder that causes severe cognitive decline and poses a significant burden on global health systems. Despite extensive research, effective treat...

Filament Health has collaborated with UCL to provide its botanical psilocybin drug candidate, PEX010, for two Phase II research studies.

A West Virginia researcher is working at the cutting edge of the study of psychedelics. Corinne Hazel is a West Virginia University microbiology student. This spring, she found a fungus that was barel...

Key legal, ethical, and compliance considerations for managed care professionals navigating the evolving landscape of psychedelic-assisted therapy include regulatory risks, data privacy challenges, re...

Despite the resurgence of research into the clinical efficacy and mechanism of action of psychedelic drugs such as such as psilocybin, LSD, DMT, and MDMA they are currently in Schedule 1 of the Misuse...

“We are encouraged by the growing body of rigorous research exploring the use of psychedelics, including psilocybin in treating treatment-resistant types of mental illness.” By Jack Gorsline, HorizonM...

Kadysh discusses PharmAla’s MDMA and the logistics of the international MDMA supply chain.

Watch three exciting book presentations that Drugreporter recorded at PS25 in Denver. Timothy Leary’s son, Zach Leary, presented his new book Your Extraordinary Mind; Wendy Tucker, Ann Shulgin’s daugh...

Recent clinical trials show that serotonergic psychedelics, including the prototypical hallucinogen lysergic acid diethylamide (LSD), possess a great …

Filament Health Announces Two Phase 2 Research Trials In Partnership With University College London

Therapeutic centers that use psychedelic compounds to treat patients will be able to open in Avon beginning in August. On Tuesday, Avon finished establishing where and under what limitations natural m...

YouTube video by The Psychedelic Scientist

The Natural Medicine Advisory Board is weighing this, with the governor's support. The drug shows therapeutic promise, along with some risks.

Here, we share Dr. Alaina Jaster’s observations from the inaugural Neurobiology of Psychedelics Gordon Research Conference, where leading scientists gathered to explore various realms of psychedelic…

Background There are few effective treatments for eating disorders (EDs), and new interventions are urgently needed. The MEDication and other drugs For Eating Disorders (“MED–FED”) survey investigated...

Scientific Reports - Quantitative and qualitative influences of spiritual connection and natural imagery on perception of art in clinical psychedelic dosing settings

Those living with chronic pain and comorbid functional disabilities are often confronted by a physically and emotionally transformative experience, im…

Regulators plan to integrate ibogaine treatment into Colorado’s psychedelic healing industry. Still, the drug faces an uncertain future.

This is the first study to investigate psychedelic retreats as a holistic therapy for veterans' mental health alongside community reintegration. Psilocybin and ayahuasca retreats significantly improve...

The Czech Senate has approved a major reform of the country’s criminal code, including a significant shift in drug policy. We discuss it with drug expert  Jindřich Vobořil.

YouTube video by MIND Foundation

The classical psychedelics (+)-lysergic acid diethylamide (LSD), psilocybin, and mescaline exert their psychedelic effects via activation of the 5-HT2…

IntroductionThe aesthetic qualities of psychedelic experiences have long been documented, but their specific contribution to therapeutic outcomes remains und...

The Natural Medicine Act made legal in Colorado something that Indigenous cultures have considered traditional for centuries. Santiago Guerra, a professor of Southwest Studies at Colorado College who ...

Kyle Rosner shares a behind-the-scenes look at MAPS Psychedelic Science 2025, including the two-night Psychedelic Playhouse and the high-stakes Psych-Tank pitch.

A new Texas law that will provide up to $50 million to study ibogaine reflects growing government interest in psychedelic therapy research for mental health treatments

Morgan Luttrell says he had never smoked anything, let alone tried drugs in his life. So the retired Navy SEAL had to ask a nearby nurse for guidance on how to inhale a psychedelic drug that was part ...